docetaxel + epirubicin + cyclophosphamide + vinorelbine + capecitabine + trastuzumab + bevacizumab

This is a multi-agent combination regimen consisting of seven drugs used in the treatment of breast cancer, particularly in advanced or high-risk cases. The regimen includes: - **Docetaxel** (a taxane): Inhibits microtubule depolymerization, disrupting mitosis and leading to cell death. - **Epirubicin** (an anthracycline): Intercalates into DNA and inhibits topoisomerase II, causing DNA damage and apoptosis. - **Cyclophosphamide** (an alkylating agent): Crosslinks DNA strands, preventing cell replication. - **Vinorelbine** (a vinca alkaloid): Inhibits microtubule assembly, blocking mitosis. - **Capecitabine** (an oral prodrug of 5-fluorouracil): Metabolized to 5-FU in tumors; inhibits thymidylate synthase and disrupts DNA synthesis[1][4]. - **Trastuzumab** (a monoclonal antibody against HER2/neu receptor): Blocks HER2 signaling pathways involved in cell proliferation[6][8]. - **Bevacizumab** (a monoclonal antibody against VEGF-A): Inhibits angiogenesis by blocking vascular endothelial growth factor A[6][8]. This combination targets multiple mechanisms critical for tumor growth—cell division, DNA replication/repair, HER2-driven signaling pathways, and tumor angiogenesis. It is considered investigational as a full seven-drug regimen but each component has established use in breast cancer therapy.